Raymond James Downgrades Genomic Health to Underperform (GHDX)
Genomic Health (NASDAQ:GHDX) was downgraded by stock analysts at Raymond James from a “market perform” rating to an “underperform” rating in a report issued on Monday, TheFlyOnTheWall.com reports.
Genomic Health (NASDAQ:GHDX) opened at 32.46 on Monday. Genomic Health has a one year low of $25.25 and a one year high of $38.99. The stock’s 50-day moving average is $33.00 and its 200-day moving average is $32.62. The company has a market cap of $994.0 million and a P/E ratio of 550.17.
Genomic Health (NASDAQ:GHDX) last announced its earnings results on Wednesday, July 31st. The company reported ($0.10) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.08) by $0.02. The company had revenue of $63.70 million for the quarter, compared to the consensus estimate of $63.91 million. During the same quarter in the prior year, the company posted $0.06 earnings per share. The company’s quarterly revenue was up 11.4% on a year-over-year basis. On average, analysts predict that Genomic Health will post $-0.12 earnings per share for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at MLV Capital raised their price target on shares of Genomic Health (NASDAQ:GHDX) from $30.00 to $35.00 in a research note to investors on Friday, August 2nd. They now have a “hold” rating on the stock. Analysts at Goldman Sachs Group Inc. downgraded shares of Genomic Health (NASDAQ:GHDX) from a “neutral” rating to a “sell” rating in a research note to investors on Tuesday, June 25th. They now have a $26.00 price target on the stock, down previously from $27.00.
Two research analysts have rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $35.67.
In other Genomic Health news, CMO Steven Shak sold 5,000 shares of Genomic Health stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $33.73, for a total transaction of $168,650.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Genomic Health, Inc (NASDAQ:GHDX) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.